Witkin J M, Barrett J E, Cook J M, Larscheid P
Pharmacol Biochem Behav. 1986 Apr;24(4):963-5. doi: 10.1016/0091-3057(86)90443-0.
Ethyl-beta-carboline-3-carboxylate (beta-CCE), inosine and Ro 15-1788 are antagonists of several actions of the benzodiazepines. These compounds can be differentiated, however, according to their ability to reverse the loss of the righting response induced by diazepam. Ro 15-1788 completely reversed effects of diazepam on the righting response of pigeons and squirrel monkeys but was ineffective against comparable effects produced by pentobarbital. Pretreatment with Ro 15-1788 protected against diazepam-induced righting loss. Neither inosine nor beta-CCE reversed diazepam-induced righting loss or acted prophylactically against this effect. Since beta-CCE has been characterized as an inverse agonist at the benzodiazepine receptor, the absence of antagonism we report would suggest that beta-CCE lacks specific pharmacological activity which opposes suppression of the righting response by diazepam. Research with these preferentially-acting antagonists may lead to the development of anxiolytics devoid of the sedative-hypnotic properties inherent in the drugs currently in a clinical use.
β-咔啉-3-羧酸乙酯(β-CCE)、肌苷和Ro 15-1788是苯二氮䓬类几种作用的拮抗剂。然而,根据它们逆转地西泮引起的翻正反射消失的能力,可以区分这些化合物。Ro 15-1788能完全逆转地西泮对鸽子和松鼠猴翻正反射的作用,但对戊巴比妥产生的类似作用无效。用Ro 15-1788预处理可预防地西泮引起的翻正反射消失。肌苷和β-CCE都不能逆转地西泮引起的翻正反射消失,也不能预防性地对抗这种作用。由于β-CCE已被表征为苯二氮䓬受体的反向激动剂,我们报告的拮抗作用的缺乏表明β-CCE缺乏对抗地西泮对翻正反射抑制的特异性药理活性。对这些优先作用的拮抗剂的研究可能会导致开发出没有目前临床使用药物所固有的镇静催眠特性的抗焦虑药。